MCM
RLAY icon

Moore Capital Management’s Relay Therapeutics RLAY Stock Holding History

Moore Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.75M Buy
+414,005
New +$6.01M 0.11% 164
2021
Q1 		– Sell
-130,162
Closed -$5.41M – 763
2020
Q4 		$5.41M Buy
+130,162
New +$5.88M 0.06% 223

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Moore Capital Management's RLAY Position: Q2 2026 in Review

Moore Capital Management opened a new position in Relay Therapeutics (RLAY) in Q2 2026: 414,005 shares worth $7.75M. The stake represents 0.11% of the portfolio and ranks #164 among its holdings. This is a return to the name: Moore Capital Management previously reported a position in RLAY as recently as Q4 2020.

Moore Capital Management first reported a position in RLAY in Q4 2020 and has held it in 2 quarters since. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Moore Capital Management held 414,005 shares of Relay Therapeutics worth $7.75M as of Q2 2026.
  • Relay Therapeutics was a new Moore Capital Management position in Q2 2026.
  • Relay Therapeutics made up 0.11% of Moore Capital Management's portfolio in Q2 2026, its #164 holding.
  • Moore Capital Management first reported a position in Relay Therapeutics in Q4 2020 and has held it in 2 quarters since.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.